Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions. (December 2022)

• Record Type: Journal Article
• Authors: Eisele, Philipp; Wittayer, Matthias; Weber, Claudia E; Platten, Michael; Schirmer, Lucas; Gass, Achim
• Is Part Of: Multiple sclerosis. Volume 28:Number 14(2022)
• Page Start: 2294
• Page End: 2298
• Publication Date: 2022-12
• Subjects: Multiple sclerosis -- magnetic resonance imaging -- iron rim lesions -- chronic active lesions; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/13524585221106338
• Languages: English
• ISSNs: 1352-4585

Abstract

We investigated the impact of disease-modifying therapies (DMTs) on the evolving tissue damage in iron rim multiple sclerosis lesions using a novel post-processing magnetic resonance imaging (MRI) approach, the T1/T2 ratio. In this study, on baseline and 1-year follow-up, T1/T2 ratios of iron rim lesions (IRLs) in patients starting DMT (dimethyl fumarate, fingolimod, ocrelizumab) did not statistically differ compared to patients without DMT. At the second follow-up, T1/T2 ratios were significantly lower in IRLs in patients without DMT ( p = 0.002), suggesting that DMTs have a beneficial delayed effect on lesion evolution and tissue matrix damage in IRLs.